Ulcerative Colitis

Real trial evidence, not just theory

Ulcerative colitis is a chronic inflammatory condition affecting the colon. Researchers have directly tested whether changing a patient's gut bacteria can help treat it. A meta-analysis combining 14 randomised controlled trials and 600 patients found that faecal microbiota transplants significantly increased the odds of combined clinical and endoscopic remission compared with standard care.

Source: Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials

A second, independent analysis agrees

A separate meta-analysis of 13 randomised trials involving 580 patients, 293 who received a transplant and 287 who did not, found clinical remission was significantly more common in the transplant group. Endoscopic remission, meaning the bowel lining itself looked measurably better on examination, was also significantly more common. Adverse event rates were similar between groups, an important safety signal alongside the benefit.

Source: Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis

Specific bacteria track with how severe it gets

Beyond transplants, researchers have found that gut bacteria levels track closely with how severe ulcerative colitis actually is. A study of 96 people, 48 newly diagnosed UC patients and 48 healthy controls, found that two beneficial bacteria groups, Faecalibacterium prausnitzii and Lactobacilli, were lower the more severe a person's disease was, while three other bacteria, Bacteroides, Haemophilus, and Veillonella, were higher the more severe it was. After six months of standard treatment, F. prausnitzii and Lactobacilli levels rose significantly, and the other three fell. People who started with especially low F. prausnitzii were more likely to relapse later, meaning this single bacteria measurement could help predict who needs closer follow-up.

Source: Clinical and Experimental Medicine, Impact of gut Microbiome alteration in Ulcerative Colitis patients on disease severity and outcome

One of the largest individual trials, involving 81 patients in Australia, gave people either a real transplant or a placebo. In the transplant group, 44% of patients reached clinical remission, 18 out of 41 people. Researchers also looked at which specific bacteria mattered most for the outcome. One bacterium in particular, Fusobacterium, stood out. People who still had high levels of Fusobacterium after treatment were less likely to be in remission, giving doctors a specific bacterium to watch for.

A separate, smaller study of 31 patients found something similar before treatment even started. Compared with their donor's gut bacteria, UC patients had more of three unhelpful bacteria, Bacteroides fragilis, Clostridium difficile, and Ruminococcus gnavus. They also had less Faecalibacterium prausnitzii, the same butyrate-producing bacterium linked to better outcomes in Crohn's disease too.

Source: The Lancet, Multidonor intensive faecal microbiota transplantation for active ulcerative colitis

Source: Long-Term Efficacy of Low-Intensity Single Donor Fecal Microbiota Transplantation in Ulcerative Colitis and Outcome-Specific Gut Bacteria

The details matter

Not every version of this treatment works equally well. Across the trials, transplants delivered orally worked better than other delivery methods. Transplants using pooled donors, meaning bacteria combined from several healthy donors rather than just one, also worked better than single-donor transplants. Timing mattered too. People who had already tried certain standard medications before their transplant, including biologics, steroids, or methotrexate, responded better to the transplant than people who hadn't. In one trial of 45 patients, transplants worked about as well as a standard prescription treatment (mesalamine enema), and gut bacteria diversity remained higher for at least three months afterward.

Source: Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials

Source: Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis

What this means for you

Ulcerative colitis needs diagnosis and ongoing management from a gastroenterologist, and faecal microbiota transplant is a specialist medical procedure, not something to attempt outside proper care. Bleeding, severe pain, or a flare that isn't responding to treatment needs prompt medical attention. Alongside standard treatment, a varied, plant-rich diet supports the same kind of gut diversity these trials measured. That's the same idea behind GutLab, everyday gut health starts with regularly feeding the microbiome a broad range of plant-rich ingredients.